Aurobindo Pharma Secures USFDA VAI Status for Telangana Unit

has received a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration for its Telangana-based Unit (WS-L), following an inspection conducted earlier, indicating that while certain observations were noted, they are not severe enough to warrant regulatory action or restrictions. This classification allows the facility to continue operations without disruption, which is a positive compliance signal for the company’s manufacturing standards and regulatory track record. While VAI status reflects the need for procedural improvements, it does not impact ongoing production or approvals, thereby maintaining business continuity in a highly regulated market like the US, which remains a key revenue driver for Indian pharmaceutical exporters.